Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nova Eye MedicalASX:EYE +3.85%53 3-Year EBITDA Growth Rate is 37.40% as of Jun. 2026, which is 270% above its 10-year median of 10.10. GuruFocus rates ASX:EYE with a GF Score™ of 53/100 and a GF Value™ of A$0.17 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 82.27% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 37.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nova Eye Medical was 75.00% per year. The lowest was -49.00% per year. And the median was 10.10% per year.
Nova Eye Medical (ASX:EYE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nova Eye Medical 3-Year EBITDA Growth Rate Related Terms
ASX:EYE vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Nova Eye Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's 3-Year EBITDA Growth Rate falls into.
Nova Eye Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 37.40% mean?
Nova Eye Medical (ASX:EYE) has a 3-Year EBITDA Growth Rate of 37.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nova Eye Medical and its competitors. This is 270% above median its historical median of 10.10. According to the industry distribution chart, Nova Eye Medical ranks #122 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 17.7%.
Is Nova Eye Medical's 3-Year EBITDA Growth Rate too high?
Nova Eye Medical's current 3-Year EBITDA Growth Rate of 37.40% is 270% above median its 10-year median of 10.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Nova Eye Medical's value of 37.40% is 361.7% above this industry median. Based on the distribution chart, Nova Eye Medical ranks #122 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nova Eye Medical has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #122 out of 688 companies for 3-Year EBITDA Growth Rate. This places Nova Eye Medical in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Nova Eye Medical's value of 37.40% is 361.7% above this benchmark. While the company's 10-year median is 10.10 vs. the industry median of 8.10, Nova Eye Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Eye Medical's current 3-Year EBITDA Growth Rate of 37.40% is 361.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current 3-Year EBITDA Growth Rate is 37.40%, which is 270% above median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.14 — trading 20.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 37.40%, which is 270% above median its 10-year median of 10.10 and 361.7% above the Medical Devices & Instruments industry median of 8.10. Nova Eye Medical's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current 3-Year EBITDA Growth Rate is 37.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of A$0.14 is trading 20.6% below its estimated GF Value™ of A$0.17.
GuruFocus considers Nova Eye Medical to be Modestly Undervalued.
Key valuation signals for ASX:EYE:
3-Year EBITDA Growth Rate: 37.40% (270% above median its 10-year median of 10.10)
GF Value™: A$0.17 vs. price of A$0.14 (20.6% below fair value)
Industry Position: 361.7% above the Medical Devices & Instruments median (#122 of 688)
No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
53GF Score
Get the complete analysis for ASX:EYE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EYE has been successfully added to your 
